HomeComparePBIO vs KMB

PBIO vs KMB: Dividend Comparison 2026

PBIO yields 166666.67% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PBIO wins by $11911377672882.57M in total portfolio value
10 years
PBIO
PBIO
● Live price
166666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11911377672882.62M
Annual income
$5,393,136,696,480,418,000.00
Full PBIO calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — PBIO vs KMB

📍 PBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPBIOKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PBIO + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PBIO pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PBIO
Annual income on $10K today (after 15% tax)
$14,166,666.67/yr
After 10yr DRIP, annual income (after tax)
$4,584,166,192,008,355,000.00/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, PBIO beats the other by $4,584,166,192,008,350,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PBIO + KMB for your $10,000?

PBIO: 50%KMB: 50%
100% KMB50/50100% PBIO
Portfolio after 10yr
$5955688836441.33M
Annual income
$2,696,568,348,240,211,500.00/yr
Blended yield
45.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

PBIO
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-50.4
Piotroski
2/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PBIO buys
0
KMB buys
0
No recent congressional trades found for PBIO or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPBIOKMB
Forward yield166666.67%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%17%
Portfolio after 10y$11911377672882.62M$45.9K
Annual income after 10y$5,393,136,696,480,418,000.00$5,222.34
Total dividends collected$11310008644767.18M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: PBIO vs KMB ($10,000, DRIP)

YearPBIO PortfolioPBIO Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$8,344,033$8,333,333.33$11,314$614.45+$8.33MPBIO
2$3,258,162,280$3,249,234,164.07$12,867$760.19+$3258.15MPBIO
3$596,362,299,915$592,876,066,275.31$14,713$945.27+$596362.29MPBIO
4$51,347,407,585,706$50,709,299,924,797.41$16,924$1,181.90+$51347407.57MPBIO
5$2,095,186,069,772,327$2,040,244,343,655,621.00$19,596$1,486.64+$2095186069.75MPBIO
6$41,143,898,865,343,200$38,902,049,770,686,810.00$22,850$1,882.16+$41143898865.32MPBIO
7$401,002,058,588,188,860$356,978,086,802,271,700.00$26,849$2,399.80+$401002058588.16MPBIO
8$2,054,879,028,737,436,700$1,625,806,826,048,074,500.00$31,812$3,083.36+$2054879028737.41MPBIO
9$6,091,813,996,637,570,000$3,893,093,435,888,512,500.00$38,033$3,994.72+$6091813996637.53MPBIO
10$11,911,377,672,882,618,000$5,393,136,696,480,418,000.00$45,918$5,222.34+$11911377672882.57MPBIO

PBIO vs KMB: Complete Analysis 2026

PBIOStock

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.

Full PBIO Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this PBIO vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PBIO vs SCHDPBIO vs JEPIPBIO vs OPBIO vs KOPBIO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.